Treatment of superficial bladder cancer: A discussion on intravesical immunotherapy and intravesical chemotherapy

European Urology, Supplements

Volumn 3, Issue 3, 2004, Pages 70-72

  Whelan, Peter ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER THERAPY; CARCINOMA IN SITU; CLINICAL TRIAL; CONFERENCE PAPER; CYSTITIS; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SUPERFICIAL CANCER; TOXICITY; TRANSURETHRAL RESECTION;

EID: 1542269010     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.02.012     Document Type: Conference Paper

References (9)

1. Lum B.L., Torti F.M. Adjuvant intravesicular pharmaco-therapy for superficial bladder cancer. J. Natl. Cancer Inst. 83:1991;682.
2. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guérin on the treatment of superficial bladder tumours. J. Urol. 116:1976;180.
3. Pawinski A.A., Sylvester R., Kurth K.H., Bouffioux C., Van der Meijden A., Parmar M.K.B, et al. A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomised clinical trials for prophylactic treatment stage TaT1 bladder cancer. J. Urol. 156:1996;1934.
4. Oosterlinck W., Kurth K.H., Schroder F.H., Bultnick Hammond B., Sylvester R, et al. A prospective European Organisation for Research and Treatment of Cancer-Genito Urinary Group randomised trial comparing transurethral resection followed by a single intravesical installation of Epirubicin or water in single stage Ta T1 papillary carcinoma of the bladder. J. Urol. 149:1993;749.
5. Kurth K.H., Denis L., Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer. 31A(11):1995;1840.
6. Lamm D.L., Riggs D.R., Traynelis C.L., Nseyo Uo. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term cause of superficial transitional cell carcinoma of the bladder, J Urol 1995;153(5):1444.
7. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumour progression and death from superficial bladder cancer. Ten year follow up of a prospective randomised trial. J Clin Oncol 1995;13:1205.
8. Sylvester R., Van der Meijden A.P.M., Lamm D.L. Intravesicle Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer; A meta-analysis of the published results of randomised trials. J. Urol. 168:2002;1964.
9. Lamm D.L., Stogdill V.D., Stogdill B.J., Crispen R.G. Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J. Urol. 135:1986;272.